Abbott Laboratories Corporation

Zhiguang Yu

Joan D Tyner

Saul A Datwyler

David J Hawksworth

Susan E Brophy

Sharmila Manoj

Dominick L Pucci

Robert N Ziemann

Bryan C Tieman

Bailin Tu

Mary S Pinkus

Carol S Ramsay

Robert C Doss

Lowell J Tyner, Legal Representative

Don M Laird

Don C Laird

David C Sogin

Lianli Chi

Donald M Laird

The present disclosure relates to glycosylated and deglycosylated human PlGF-1, methods of using the glycosylated and deglycosylated human PlGF-1, antibodies that bind to human PlGF-1, methods of using the antibodies and human PlGF-1 immunoassays and kits.

PlGF-1 assay and kits and components thereof

An isolated antibody that specifically binds to sFlt-1 or a fragment thereof having (i) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO: 2, (ii) a variable light domain region comprising the amino acid sequence of SEQ ID NO: 4, or (iii) both (i) and (ii), a pharmaceutical composition and a kit comprising such an antibody, a method of making such an antibody, a method of determining the presence, amount or concentration of sFlt-1 or a fragment thereof in a test sample, a method of treating a patient in therapeutic or prophylactic need of an antagonist of sFlt-1, an isolated nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of (i) SEQ ID NO: 2, (ii) SEQ ID NO: 4, or (iii) both (i) and (ii), optionally as part of a vector, and a host cell comprising and expressing such a nucleic acid.

Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making

Growing community of inventors

Libertyville, IL, United States of America

Zhiguang Yu